This retrospective study evaluated the feasibility, safety, and short-term effectiveness of prostatic artery embolization (PAE) using n-butyl cyanoacrylate (nBCA) glue embolization in 244 patients from June 2022 through May 2024. Technical success, defined as bilateral glue embolization, was achieved in 95% of cases. The median fluoroscopy time was 22.2 minutes (interquartile range [IQR], 17.1-30.0 minutes), and the median air kerma was 753 mGy (IQR, 417-1,559 mGy). Compared with baseline, statistically significant improvements were observed at 7.1 weeks for the International Prostate Symptom Score (9.5 [SD ± 6.0] vs 20.5 [SD ± 6.7]; P < .01), quality of life (1.8 [SD ± 1.5] vs 4.0 [SD ± 1.1]; P < .01), Qmax (10.4 mL/s [SD ± 6.3] vs 6.1 mL/s [SD ± 2.5]; P < .01), and prostate grand volume at 6 months (113.3 mL [SD ± 69.3] vs 156.6 mL [SD ± 104.6]; P < .01). These results demonstrate the use of nBCA for PAE as a technically feasible and safe option with excellent short-term outcomes.
Copyright © 2024 SIR. Published by Elsevier Inc. All rights reserved.